US recommends ‘pause’ to Johnson & Johnson jab rollout over blood clot fears


The US Food and Drug Administration has recommended a “pause” to the rollout of the Johnson & Johnson COVID vaccine so it can investigate reports of blood clots.

Officials say they are looking into six reported cases “of a rare & severe type of blood clot in individuals after receiving the vaccine”.

“Right now, these adverse events appear to be extremely rare,” the FDA said in a statement on Twitter.

It said until the cases had been assessed for their potential significance, “we are recommending this pause”.

“This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot,” it added.

Articles You May Like

Bodycam video shows moment Nashville school attacker was shot dead by police
Environment campaigners ‘poised to act’ if government falls short on net-zero policy
Energy agency chief warns transition to renewables is way off track, issues warning on stranded assets
EU agrees to ramp up 2030 renewable energy targets, accelerating shift from fossil fuels
UK to join Indo-Pacific trade bloc in biggest trade deal since Brexit